TOMI Seeks NSF Certification to Expand Decontamination Tech in Life Sciences
Event summary
- TOMI is pursuing NSF certification for its SteraMist iHP technology to address pharmaceutical, biotech, and cleanroom decontamination markets.
- The company and partner Total Clean Air will present before the NSF Joint Committee on Biosafety Cabinets on June 17, 2026.
- NSF certification could validate SteraMist's effectiveness, repeatability, and material compatibility for highly regulated industries.
- Target markets include pharmaceutical production, vaccine manufacturing, and cell/gene therapy labs, representing billions in annual spending.
The big picture
TOMI's push for NSF certification aligns with the life sciences industry's increasing investment in contamination-control technologies, driven by biologics manufacturing, cell/gene therapy, and vaccine development. Success could position SteraMist as a validated standard in highly regulated environments, expanding TOMI's addressable market and recurring revenue streams. The certification process represents a strategic milestone in TOMI's efforts to penetrate multi-billion-dollar decontamination markets.
What we're watching
- Certification Timeline
- The pace at which TOMI secures NSF certification will determine its ability to capitalize on high-growth contamination-control markets.
- Market Adoption
- Whether NSF certification accelerates purchasing decisions among pharmaceutical manufacturers and biosafety officers.
- Competitive Positioning
- How TOMI leverages certification to differentiate SteraMist in a crowded life sciences decontamination space.
Related topics